Aflibercept 2Mg/0.05Ml Inj,Oph

DRUG4 trials

Sponsors

EyePoint Pharmaceuticals, Inc., Zhongshan Ophthalmic Center, Sun Yat-sen University, Al-Mustansiriyah University

Conditions

Diabetic Macular EdemaDiabetic MaculopathyWet Age-related Macular Degeneration

Phase 2

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

CompletedNCT05381948

EyePoint Pharmaceuticals, Inc.Wet Age-related Macular Degeneration

Start: 2022-06-30End: 2024-04-24Updated: 2025-10-15

Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

CompletedNCT06099184

EyePoint Pharmaceuticals, Inc.Diabetic Macular Edema

Start: 2024-01-15End: 2024-10-24Updated: 2025-03-04

Phase 4

Aflibercept and Bevacizumab for Diabetic Maculopathies

RecruitingNCT06850571

Al-Mustansiriyah UniversityDiabetic Maculopathy

Start: 2025-02-20End: 2025-12-01Target: 102Updated: 2025-09-19

Unknown Phase

Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT

RecruitingNCT06610747

Zhongshan Ophthalmic Center, Sun Yat-sen UniversityDiabetic Macular Edema

Start: 2024-10-28End: 2027-04-30Target: 308Updated: 2025-01-22

Related Papers

Nonclinical study of ixo-vec gene therapy for nAMD supports efficacy for a human dose of 6E10 vg/eye and staggered dosing of fellow eyes

Molecular Therapy — Methods & Clinical Development2025-02-105 citations